Venlafaxine for Hot Flashes: Evidence, Dosing, and Safety

Venlafaxine is an SNRI antidepressant the FDA approved in 1997, sold first as Effexor and then Effexor XR. Its approved uses are major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder. Hot flashes are not an approved use.

Prescribing it for hot flashes is off-label, which means a clinician uses an approved drug for a purpose the FDA label does not list. Off-label prescribing is legal, common, and routine in menopause care. It is not the same as an unproven or experimental treatment. The distinction matters: the trial evidence for hot flashes is strong, but the FDA has never reviewed venlafaxine for that purpose, so no one should call this use FDA approved.

If you want the wider picture of which non-hormonal drugs have evidence behind them, see the overview of non-hormonal hot flash treatment.

Venlafaxine appears to steady the brain's temperature control rather than touch hormones directly. Hot flashes are tied to falling estrogen, which narrows the thermoregulatory zone in the hypothalamus, the part of the brain that decides when the body is too hot. With a narrower zone, small shifts in core temperature trigger the flushing and sweating of a hot flash.

Serotonin and norepinephrine help set that zone, and venlafaxine raises the signaling of both. The leading explanation is that this widens the thermoregulatory zone back toward normal, so the body tolerates ordinary temperature swings without a flash. The exact mechanism is not fully settled, but the effect on symptoms is measurable and shows up quickly, within weeks rather than the longer timeline seen when the same drug is used for mood.

Venlafaxine suits women who cannot take estrogen or would rather not, which is the central reason a non-hormonal option exists. That group includes women with estrogen-sensitive cancers, a clotting history, or a personal preference to avoid hormones. For a fuller look at the choices in this situation, see what to do about hot flashes when you can't take estrogen.

Breast cancer survivors are a specific and important case. Many take tamoxifen, which the body must convert into an active form called endoxifen using the liver enzyme CYP2D6. Some antidepressants block that enzyme and can lower endoxifen, which raises a concern about blunting tamoxifen's benefit. Venlafaxine is only a weak CYP2D6 inhibitor and lowers endoxifen very little, so it is generally considered compatible with tamoxifen. Paroxetine, by contrast, is a strong CYP2D6 inhibitor and is usually avoided in women on tamoxifen. This difference is a large part of why venlafaxine is often the first non-hormonal choice after breast cancer. The dedicated guide on hot flashes after breast cancer covers this in more depth.

The strongest direct evidence comes from the MsFLASH trial, which compared venlafaxine against estrogen head to head. The trial randomized 339 perimenopausal and postmenopausal women with bothersome hot flashes to low-dose oral estradiol 0.5 mg, venlafaxine extended-release 75 mg, or placebo for eight weeks. Venlafaxine cut daily hot flashes by about 48%, estradiol cut them by about 53%, and placebo by about 29%. Both active drugs beat placebo, and the gap between venlafaxine and estradiol was small and not statistically significant, which the authors read as a difference of uncertain clinical importance (Joffe 2014).

Earlier work pointed the same way. A randomized placebo-controlled trial in breast cancer survivors and women avoiding hormones found venlafaxine cut hot flash scores by 37% at 75 mg and 61% at higher doses, against 27% for placebo over four weeks, with more side effects at the higher doses (Loprinzi 2000). That trial is part of why venlafaxine became a standard non-hormonal option in oncology.

Guidelines reflect this evidence. The 2023 non-hormone therapy position statement of the Menopause Society lists SSRIs and SNRIs, the class that includes venlafaxine, among its recommended treatments for hot flashes at its highest evidence tier, alongside cognitive behavioral therapy, hypnosis, gabapentin, and fezolinetant (NAMS 2023). The evidence is consistent: venlafaxine helps, and while estrogen may edge it out, the difference is modest.

Hot flash dosing is low, usually lower than the doses used for depression. A common approach starts at venlafaxine extended-release 37.5 mg daily for about a week to limit early nausea, then moves to 75 mg daily. The MsFLASH and breast cancer trials used 75 mg as the working dose, and higher doses add more side effects without a clear gain for hot flashes.

The response is quick. Most women notice fewer or milder flashes within about two weeks, much sooner than the four to six weeks an antidepressant often needs to lift mood. If there is no benefit after a few weeks at a steady dose, that is useful information for adjusting the plan with a clinician.

Most women tolerate venlafaxine, and the common side effects are mild and often fade. Nausea is the most frequent and tends to be worse in the first days, which is why starting low helps. Dry mouth, constipation, and reduced appetite also show up in the trials. At higher doses venlafaxine can raise blood pressure, so blood pressure is worth checking before starting and during treatment, and a sustained rise may call for a lower dose or a switch.

Venlafaxine should not be stopped abruptly. Doing so can cause discontinuation symptoms such as dizziness, nausea, irritability, and electric-shock sensations, so the dose is tapered down gradually when it is time to stop. As an antidepressant, it also carries the class warnings that apply to this drug family, including a boxed warning about suicidal thinking and behavior in younger people, which a prescriber will review.

Venlafaxine is not right for everyone. Tell a clinician about every medicine and supplement you take so they can check for interactions before you start. The main cautions are:

• Do not take venlafaxine with a monoamine oxidase inhibitor (MAOI), or within 14 days of stopping one, because the combination can cause serotonin syndrome, a serious and sometimes fatal reaction.
• Use care when combining venlafaxine with other serotonergic drugs, including other antidepressants, triptans, tramadol, and St. John's wort, because of the added serotonin syndrome risk.
• Control high blood pressure before starting, since venlafaxine can raise it further.
• Discuss any history of glaucoma, seizures, bleeding problems, or low sodium, all of which the label flags.
• Do not stop the drug suddenly; a taper is needed to avoid discontinuation symptoms.